Korro Bio Aktie
Marktkapitalisierung
144,32 Mio. $
144,32 Mio. $
Streubesitz
0%
KGV
-0,64
Index-Zuordnung
-
Frequency Therapeutics Inc Unternehmensprofil
Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. Its lead product candidate is KRRO-110 which is in Phase 1/2 clinical trial for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinsons disease, Amyotrophic lateral sclerosis, severe drug-associated anesthetics, and other pain indications. Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S to treat cardiometabolic diseases. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Vorstand
Dr. Ram Aiyar MBA, Ph.D.
CEO, Präsident, Interim-CFO, Hauptfinanzvorstand & Direktor
Dr. Loic Vincent Ph.D.
Wissenschaftlicher Leiter
Dr. Jeffrey M. Cerio J.D., Pharm.D.
Senior VP, Chefsyndikus & Unternehmenssekretär
Dr. Andrew Fraley Ph.D.
Mitbegründer& Berater
Dr. Joshua Rosenthal Ph.D.
Mitbegründer& Berater
Herr Todd Chappell M.B.A.
Operativer Geschäftsführer
Herr Oliver Dolan
Senior VP of Finance & Hauptverantwortlicher für das Rechnungswesen
Frau Stephanie Engels
Verantwortlicher für das Personalwesen
Dr. Gaozhong Zhu Ph.D.
SVP für Chemie, Produktion und Kontrolle & Technischer Betrieb
Aktionärsstruktur
Termine
Stammdaten
| Nennwert/Aktie | - |
| Land | USA |
| Währung | USD |
| Branche | Biotechnologie |
| Aktientyp | - |
| Sektor | Gesundheit |
| Gattung | - |
Quelle: Leeway